Kaleb Lambeth, MD

Texas Heart Institute Positions

Education

  • Medical School:

    McGovern Medical School at The University of Texas Health Science Center at Houston

  • Residency:

    Johns Hopkins University

  • Fellowships:

    The Texas Heart Institute (Cardiovascular Disease)

Honors, Awards and Memberships

  • Tauber Outstanding Fellow of the Year Award, 2024

Publications

4862227 PCL6ADRQ 1 alternatives-to-animal-experimentation 10 date desc Lambeth 37956 https://www.texasheart.org/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%225CSKUIVX%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Segar%20et%20al.%22%2C%22parsedDate%22%3A%222023-08-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BSegar%2C%20M.%20W.%2C%20Zhang%2C%20A.%2C%20Paisley%2C%20R.%20D.%20et%20al.%20%282023%29.%20Risk%20stratification%20in%20patients%20who%20underwent%20percutaneous%20left%20atrial%20appendage%20occlusion.%20%26lt%3Bi%26gt%3BAm%20J%20Cardiol%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B200%26lt%3B%5C%2Fi%26gt%3B%2C%2050%26%23x2013%3B56.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.amjcard.2023.05.019%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.amjcard.2023.05.019%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Risk%20stratification%20in%20patients%20who%20underwent%20percutaneous%20left%20atrial%20appendage%20occlusion%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%20W.%22%2C%22lastName%22%3A%22Segar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Allan%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20D.%22%2C%22lastName%22%3A%22Paisley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anish%22%2C%22lastName%22%3A%22Badjatiya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kaleb%20D.%22%2C%22lastName%22%3A%22Lambeth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karen%22%2C%22lastName%22%3A%22Mullins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mehdi%22%2C%22lastName%22%3A%22Razavi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joanna%20E.%22%2C%22lastName%22%3A%22Molina-Razavi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdi%22%2C%22lastName%22%3A%22Rasekh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mohammad%22%2C%22lastName%22%3A%22Saeed%22%7D%5D%2C%22abstractNote%22%3A%22Left%20atrial%20appendage%20occlusion%20%28LAAO%29%20is%20effective%20in%20preventing%20thromboembolism.%20Risk%20stratification%20tools%20could%20help%20identify%20patients%20at%20risk%20for%20early%20mortality%20after%20LAAO.%20In%20this%20study%2C%20we%20validated%20and%20recalibrated%20a%20clinical%20risk%20score%20%28CRS%29%20to%20predict%20risk%20of%20all-cause%20mortality%20after%20LAAO.%20This%20study%20used%20data%20from%20patients%20who%20underwent%20LAAO%20in%20a%20single-center%2C%20tertiary%20hospital.%20A%20previously%20developed%20CRS%20using%205%20variables%20%28age%2C%20body%20mass%20index%20%5BBMI%5D%2C%20diabetes%2C%20heart%20failure%2C%20and%20estimated%20glomerular%20filtration%20rate%29%20was%20applied%20to%20each%20patient%20to%20assess%20risk%20of%20all-cause%20mortality%20at%201%20and%202%5Cu00a0years.%20The%20CRS%20was%20recalibrated%20to%20the%20present%20study%20cohort%20and%20compared%20with%20established%20atrial%20fibrillation-specific%20%28CHA2DS2-VASc%20and%20HAS-BLED%29%20and%20generalized%20%28Walter%20index%29%20risk%20scores.%20Cox%20proportional%20hazard%20models%20were%20used%20to%20assess%20the%20risk%20of%20mortality%20and%20discrimination%20was%20assessed%20by%20Harrel%20C-index.%20Among%20223%20patients%2C%20the%201-%20and%202-year%20mortality%20rates%20were%206.7%25%20and%2011.2%25%2C%20respectively.%20With%20the%20original%20CRS%2C%20only%20low%20BMI%20%28%26lt%3B23%5Cu00a0kg%5C%2Fm2%29%20was%20a%20significant%20predictor%20of%20all-cause%20mortality%20%28hazard%20ratio%20%5BHR%5D%20%5B95%25%20CI%5D%202.76%20%5B1.03%20to%207.35%5D%3B%20p%5Cu00a0%3D%5Cu00a00.04%29.%20With%20recalibration%2C%20BMI%20%26lt%3B29%5Cu00a0kg%5C%2Fm2%20and%20estimated%20glomerular%20filtration%20rate%20%26lt%3B60%5Cu00a0ml%5C%2Fmin%5C%2F1.73%5Cu00a0m2%20were%20significantly%20associated%20with%20an%20increased%20risk%20of%20death%20%28HR%20%5B95%25%20CI%5D%203.24%20%5B1.29%20to%208.13%5D%20and%202.48%20%5B1.07%20to%205.74%5D%2C%20respectively%29%2C%20with%20a%20trend%20toward%20significance%20noted%20for%20history%20of%20heart%20failure%20%28HR%20%5B95%25%20CI%5D%202.13%20%5B0.97%20to%204.67%5D%2C%20p%5Cu00a0%3D%5Cu00a00.06%29.%20Recalibration%20improved%20the%20discriminative%20ability%20of%20the%20CRS%20from%200.65%20to%200.70%20and%20significantly%20outperformed%20established%20risk%20scores%20%28CHA2DS2-VASc%5Cu00a0%3D%5Cu00a00.58%2C%20HAS-BLED%5Cu00a0%3D%5Cu00a00.55%2C%20Walter%20index%5Cu00a0%3D%5Cu00a00.62%29.%20In%20this%20single-center%2C%20observational%20study%2C%20the%20recalibrated%20CRS%20accurately%20risk%20stratified%20patients%20who%20underwent%20LAAO%20and%20significantly%20outperformed%20established%20atrial%20fibrillation-specific%20and%20generalized%20risk%20scores.%20In%20conclusion%2C%20clinical%20risk%20scores%20should%20be%20considered%20as%20an%20adjunct%20to%20standard%20of%20care%20when%20evaluating%20a%20patient%26%23039%3Bs%20candidacy%20for%20LAAO.%22%2C%22date%22%3A%222023-08-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.amjcard.2023.05.019%22%2C%22ISSN%22%3A%221879-1913%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MQPA457U%22%2C%22DYX9DYCW%22%2C%22MDMKKD23%22%2C%22Q5SGFS6G%22%2C%22B842TXVQ%22%2C%22PCL6ADRQ%22%2C%22TU4G2TDX%22%2C%22Q46ISS7S%22%2C%224U5B8N6T%22%5D%2C%22dateModified%22%3A%222023-07-21T19%3A10%3A02Z%22%7D%7D%2C%7B%22key%22%3A%223UKIE67Q%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Jacobsen%20et%20al.%22%2C%22parsedDate%22%3A%222021-09-14%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BJacobsen%2C%20A.%20P.%2C%20Lim%2C%20Z.%20L.%2C%20Chang%2C%20B.%20et%20al.%20%282021%29.%20A%20transatlantic%20comparison%20of%20patient-reported%20access%20to%20and%20use%20of%20aspirin%20in%20contemporary%20preventive%20cardiology.%20%26lt%3Bi%26gt%3BJ%20Am%20Coll%20Cardiol%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B78%26lt%3B%5C%2Fi%26gt%3B%2C%201193%26%23x2013%3B1195.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jacc.2021.07.015%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jacc.2021.07.015%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22A%20transatlantic%20comparison%20of%20patient-reported%20access%20to%20and%20use%20of%20aspirin%20in%20contemporary%20preventive%20cardiology%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alan%20P.%22%2C%22lastName%22%3A%22Jacobsen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zi%20Lun%22%2C%22lastName%22%3A%22Lim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Blair%22%2C%22lastName%22%3A%22Chang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kaleb%20D.%22%2C%22lastName%22%3A%22Lambeth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%20M.%22%2C%22lastName%22%3A%22Das%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Colin%22%2C%22lastName%22%3A%22Gorry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22McCague%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22William%22%2C%22lastName%22%3A%22Wijns%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%20W.%20J.%20C.%22%2C%22lastName%22%3A%22Serruys%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roger%20S.%22%2C%22lastName%22%3A%22Blumenthal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Seth%20S.%22%2C%22lastName%22%3A%22Martin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20W.%22%2C%22lastName%22%3A%22McEvoy%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22SEP%2014%202021%22%2C%22language%22%3A%22English%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jacc.2021.07.015%22%2C%22ISSN%22%3A%220735-1097%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.webofscience.com%5C%2Fwos%5C%2Fwoscc%5C%2Fsummary%5C%2F726219df-1371-453e-899a-52b5b7d212d3-094adb41%5C%2Frelevance%5C%2F1%22%2C%22collections%22%3A%5B%22PCL6ADRQ%22%2C%22X2D36SJL%22%5D%2C%22dateModified%22%3A%222021-11-03T19%3A08%3A14Z%22%7D%7D%2C%7B%22key%22%3A%22N5W8YIFK%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Nam%20et%20al.%22%2C%22parsedDate%22%3A%222013-04-02%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BNam%2C%20Y.-J.%2C%20Song%2C%20K.%2C%20Luo%2C%20X.%20et%20al.%20%282013%29.%20Reprogramming%20of%20human%20fibroblasts%20toward%20a%20cardiac%20fate.%20%26lt%3Bi%26gt%3BProc%20Natl%20Acad%20Sci%20U%20S%20A%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B110%26lt%3B%5C%2Fi%26gt%3B%2C%205588%26%23x2013%3B5593.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1073%5C%2Fpnas.1301019110%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1073%5C%2Fpnas.1301019110%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Reprogramming%20of%20human%20fibroblasts%20toward%20a%20cardiac%20fate%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Young-Jae%22%2C%22lastName%22%3A%22Nam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kunhua%22%2C%22lastName%22%3A%22Song%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xiang%22%2C%22lastName%22%3A%22Luo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edward%22%2C%22lastName%22%3A%22Daniel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kaleb%22%2C%22lastName%22%3A%22Lambeth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katherine%22%2C%22lastName%22%3A%22West%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20A.%22%2C%22lastName%22%3A%22Hill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20Michael%22%2C%22lastName%22%3A%22DiMaio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Linda%20A.%22%2C%22lastName%22%3A%22Baker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rhonda%22%2C%22lastName%22%3A%22Bassel-Duby%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%20N.%22%2C%22lastName%22%3A%22Olson%22%7D%5D%2C%22abstractNote%22%3A%22Reprogramming%20of%20mouse%20fibroblasts%20toward%20a%20myocardial%20cell%20fate%20by%20forced%20expression%20of%20cardiac%20transcription%20factors%20or%20microRNAs%20has%20recently%20been%20demonstrated.%20The%20potential%20clinical%20applicability%20of%20these%20findings%20is%20based%20on%20the%20minimal%20regenerative%20potential%20of%20the%20adult%20human%20heart%20and%20the%20limited%20availability%20of%20human%20heart%20tissue.%20An%20initial%20but%20mandatory%20step%20toward%20clinical%20application%20of%20this%20approach%20is%20to%20establish%20conditions%20for%20conversion%20of%20adult%20human%20fibroblasts%20to%20a%20cardiac%20phenotype.%20Toward%20this%20goal%2C%20we%20sought%20to%20determine%20the%20optimal%20combination%20of%20factors%20necessary%20and%20sufficient%20for%20direct%20myocardial%20reprogramming%20of%20human%20fibroblasts.%20Here%20we%20show%20that%20four%20human%20cardiac%20transcription%20factors%2C%20including%20GATA%20binding%20protein%204%2C%20Hand2%2C%20T-box5%2C%20and%20myocardin%2C%20and%20two%20microRNAs%2C%20miR-1%20and%20miR-133%2C%20activated%20cardiac%20marker%20expression%20in%20neonatal%20and%20adult%20human%20fibroblasts.%20After%20maintenance%20in%20culture%20for%204-11%20wk%2C%20human%20fibroblasts%20reprogrammed%20with%20these%20proteins%20and%20microRNAs%20displayed%20sarcomere-like%20structures%20and%20calcium%20transients%2C%20and%20a%20small%20subset%20of%20such%20cells%20exhibited%20spontaneous%20contractility.%20These%20phenotypic%20changes%20were%20accompanied%20by%20expression%20of%20a%20broad%20range%20of%20cardiac%20genes%20and%20suppression%20of%20nonmyocyte%20genes.%20These%20findings%20indicate%20that%20human%20fibroblasts%20can%20be%20reprogrammed%20to%20cardiac-like%20myocytes%20by%20forced%20expression%20of%20cardiac%20transcription%20factors%20with%20muscle-specific%20microRNAs%20and%20represent%20a%20step%20toward%20possible%20therapeutic%20application%20of%20this%20reprogramming%20approach.%22%2C%22date%22%3A%22APR%202%202013%22%2C%22language%22%3A%22English%22%2C%22DOI%22%3A%2210.1073%5C%2Fpnas.1301019110%22%2C%22ISSN%22%3A%220027-8424%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.webofscience.com%5C%2Fwos%5C%2Fwoscc%5C%2Fsummary%5C%2F726219df-1371-453e-899a-52b5b7d212d3-094adb41%5C%2Frelevance%5C%2F1%22%2C%22collections%22%3A%5B%22PCL6ADRQ%22%2C%22X2D36SJL%22%5D%2C%22dateModified%22%3A%222021-09-21T18%3A34%3A14Z%22%7D%7D%5D%7D
Segar, M. W., Zhang, A., Paisley, R. D. et al. (2023). Risk stratification in patients who underwent percutaneous left atrial appendage occlusion. Am J Cardiol 200, 50–56. https://doi.org/10.1016/j.amjcard.2023.05.019.
Jacobsen, A. P., Lim, Z. L., Chang, B. et al. (2021). A transatlantic comparison of patient-reported access to and use of aspirin in contemporary preventive cardiology. J Am Coll Cardiol 78, 1193–1195. https://doi.org/10.1016/j.jacc.2021.07.015.
Nam, Y.-J., Song, K., Luo, X. et al. (2013). Reprogramming of human fibroblasts toward a cardiac fate. Proc Natl Acad Sci U S A 110, 5588–5593. https://doi.org/10.1073/pnas.1301019110.